AZD8330   Click here for help

GtoPdb Ligand ID: 8474

Synonyms: ARRY-424704 | ARRY-704 | AZD-8330
Compound class: Synthetic organic
Comment: AZD8330 is a non-ATP competitive inhibitor of the kinases MEK 1 and MEK2. Clinical development was terminated at Phase 1.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 4
Hydrogen bond donors 3
Rotatable bonds 7
Topological polar surface area 92.59
Molecular weight 461.02
XLogP 4.2
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES OCCONC(=O)c1cc(C)c(=O)n(c1Nc1ccc(cc1F)I)C
Isomeric SMILES OCCONC(=O)c1cc(C)c(=O)n(c1Nc1ccc(cc1F)I)C
InChI InChI=1S/C16H17FIN3O4/c1-9-7-11(15(23)20-25-6-5-22)14(21(2)16(9)24)19-13-4-3-10(18)8-12(13)17/h3-4,7-8,19,22H,5-6H2,1-2H3,(H,20,23)
InChI Key RWEVIPRMPFNTLO-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
AZD8330 reached Phase 1 clinical trial in patients with advanced malignancies, although the record for NCT00454090 has not been updated since 2011.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
MEK1 and -2 (MAP2K1 and MAP2K2 respectively) activate the serine/threonine kinases ERK1 and ERK2 (MAPK3 and MAPK1 respectively), with this pathway playing important roles in cellular proliferation, differentiation, apoptosis, migration, and invasion. Thus agents which inhibit these enzymes are being investigated as novel anti-cancer therapeutics.